Streetbeat News

Earnings

VINC

Vincerx Pharma's shares are trading lower following the presentation of preliminary Phase 1 data for VIP236 and updates on its pipeline progress at the AACR Annual Meeting 2024.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 11:12 am

TLRY

Tilray's stock price dropped following its Q3 earnings miss and the announcement that it no longer anticipates achieving positive adjusted free cash flow for fiscal year 2024.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 11:11 am

NEOG

Neogen has revised its FY2024 Adjusted EBITDA guidance downwards to $210M-$215M from the previously projected range of $230M-$240M.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 11:09 am

NEOG

Neogen has revised its FY2024 sales guidance downwards to $910M-$920M from the previous estimate of $935M-$955M, below the consensus of $938.16M. The adjustment is due to slower-than-expected recovery in order fulfillment rates, affecting the ability to meet demand. Capital expenditures are still expected to be around $130M, with $100M allocated for the integration of 3M's Food Safety Division.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 11:08 am

TLRY

Tilray Brands reported Q3 sales of $188.340 million, missing the analyst consensus estimate of $198.500 million by 5.12%. This represents a 29.36% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 11:07 am

CGNT

Cognyte Software projects its FY25 revenue to be $340M, marking an 8.5% growth from the previous year, with an EPS loss of $0.13, better than the estimated loss of $0.18.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 11:06 am

ALKS

Alkermes announced positive topline results from its Phase 1b study of ALKS 2680, a treatment for patients with Narcolepsy Type 2 and Idiopathic Hypersomnia. This marks a significant milestone in the development of a potential new treatment option for these sleep disorders.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 11:03 am

CGNT

Cognyte Software (NASDAQ:CGNT) reported Q4 2024 adjusted EPS of $(0.23), surpassing the $(0.27) estimate, with sales of $83.691M exceeding the $80.108M forecast. This represents a 13.75% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 11:03 am

NEOG

Neogen (NASDAQ:NEOG) reported Q3 2024 adjusted EPS of $0.12, missing the $0.14 estimate, and sales of $228.812M, below the $230.011M estimate. This represents a 4.84% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 11:02 am

PSMT

QQQ

SPY

TLRY

WDFC

US stock futures show minimal movement amid concerns over inflation data and mixed market signals. Analysts remain optimistic, predicting S&P 500 earnings growth due to strong economic momentum and AI investment. The SPDR S&P 500 ETF Trust and Invesco QQQ ETF saw slight premarket declines. Analysts highlight the potential for continued equity market growth, citing historical trends and expectations for slowing inflation. Key earnings reports are expected from Tilray Brands, PriceSmart, and WD-40 Company.

Portfolio Pulse from Shanthi Rexaline

April 09, 2024 | 11:02 am